News | April 14, 2009

Biotronik Announces First U.S. Implant Of Lumax 540 Series for Heart Failure Patients

April 14, 2009 - Biotronik Inc. announced yesterday the first U.S. implant of the next-generation Lumax 540 Series defibrillator for treating patients with heart failure.

The Lumax 540 Series was recently approved by the FDA.

The first U.S. implant of the new Lumax 540 Series was performed by Leon Feldman, M.D., FACC, co-director of electrophysiology and cardiology section chief at Eisenhower Medical Center in Rancho Mirage, Calif.

“The patient presented with very complex needs: ongoing bradycardia, recurrent ventricular tachycardia, and progressive heart failure all at once,” Dr. Feldman said. “The patient will benefit from the advanced capabilities of the Lumax 5 Series defibrillator.”

Heart failure is on the rise in the U.S., affecting 5 million people with 550,000 new cases each year. Fortunately, therapies are available to enhance the quality of life of a heart failure patient.

“The patient already received the highest dose of beta blockers and ACE inhibitors that he could handle and was still in severe heart failure,” Dr. Feldman said, who said a cardiac resynchronization therapy defibrillator (CRT-D) was the perfect solution. “I’ve had great success with previous-generation Biotronik devices and have confidence in the construction of the device and lead technology. Also, I’m a big proponent of Home Monitoring for the patient, which can remotely and rapidly detect onset of atrial fibrillation, for which this patient is at risk.”

Dr. Feldman said the benefits that Biotronik's Home Monitoring system offers him and the patient early notification of VF and VT, which allows him to modify therapy and avoid unnecessary shocks.

For more information: www.biotronik.com

Related Content

Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD)| September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Predictive Models May Help Determine Which Patients Benefit From ICDs
News | Implantable Cardioverter Defibrillator (ICD)| July 06, 2017
Two predictive models may help cardiologists decide which patients would most benefit from an implantable cardioverter...
Videos | Implantable Cardioverter Defibrillator (ICD)| June 01, 2017
Lucas Boersma, M.D., Ph.D., FESC, St.
The Unify ICD is one of the SJM devices in an FDA warning letter
Feature | Implantable Cardioverter Defibrillator (ICD)| April 14, 2017 | Dave Fornell
April 14, 2017 — The U.S. Food and Drug Administration (FDA) sent a warning letter to Abbott/St.
ICDs, non-ischemic cardiomyopathy, University of Alabama at Birmingham study, Circulation
News | Implantable Cardioverter Defibrillator (ICD)| January 18, 2017
A new study published in Circulation has found there is a 23 percent risk in reduction of all-cause mortality in non-...
ICDs, implantable cardioverter defibrillators, survival rate, elderly patients, JACC study
News | Implantable Cardioverter Defibrillator (ICD)| January 17, 2017
Of patients over age 65 who received an implantable cardioverter-defibrillator (ICD) after surviving sudden cardiac...
Overlay Init